- Home
- SCYX vs COCH Comparison
SCYX vs COCH Comparison
Compare SCYX & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- COCH
- Stock Information
- Founded
- SCYX 1999
- COCH 1995
- Country
- SCYX United States
- COCH United States
- Employees
- SCYX N/A
- COCH N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- COCH Blank Checks
- Sector
- SCYX Health Care
- COCH Finance
- Exchange
- SCYX Nasdaq
- COCH Nasdaq
- Market Cap
- SCYX 28.5M
- COCH 31.6M
- IPO Year
- SCYX 2014
- COCH N/A
- Fundamental
- Price
- SCYX $0.71
- COCH $1.46
- Analyst Decision
- SCYX
- COCH Strong Buy
- Analyst Count
- SCYX 0
- COCH 2
- Target Price
- SCYX N/A
- COCH $9.25
- AVG Volume (30 Days)
- SCYX 115.9K
- COCH 19.6K
- Earning Date
- SCYX 08-07-2025
- COCH 08-11-2025
- Dividend Yield
- SCYX N/A
- COCH N/A
- EPS Growth
- SCYX N/A
- COCH N/A
- EPS
- SCYX N/A
- COCH N/A
- Revenue
- SCYX $2,630,000.00
- COCH $212,000.00
- Revenue This Year
- SCYX $463.61
- COCH $8.04
- Revenue Next Year
- SCYX $310.80
- COCH $15.39
- P/E Ratio
- SCYX N/A
- COCH N/A
- Revenue Growth
- SCYX N/A
- COCH N/A
- 52 Week Low
- SCYX $0.66
- COCH $1.21
- 52 Week High
- SCYX $2.29
- COCH $3.99
- Technical
- Relative Strength Index (RSI)
- SCYX 39.58
- COCH 48.52
- Support Level
- SCYX $0.70
- COCH $1.40
- Resistance Level
- SCYX $0.75
- COCH $1.58
- Average True Range (ATR)
- SCYX 0.05
- COCH 0.09
- MACD
- SCYX 0.00
- COCH 0.01
- Stochastic Oscillator
- SCYX 28.80
- COCH 47.83
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.